Search

Cost conundrum: the investment in clinical trials remains the same but approved drugs will have a smaller market. So how is Personalised Medicine to be financed?

With 20 years of experience behind him, ACES winner Nigel Brown believes companies today spend too much money – and energy – on water purification.

Karl Tryggvason, former Dean of Research at Karolinska, admits a ‘mistake’ but tells Science|Business it wasn’t a sacking offence.

A new ‘vision’ from Brussels offers something for everyone – including research and innovation. But in the end, it comes off as empty rhetoric.

The President of the Karolinska Instituet, Harriet Wallberg-Henriksson, has been forced to dismiss a key figure after uncovering undue influence in allocating funds.

The first €1M grants from the EIT will be signed next week. Now the real work begins, chairman Martin Schuurmans tells Science|Business.

After 7 years of deliberation, the European Commission is to authorise the Amflora genetically modified potato to be cultivated for industrial purposes.

The Administrative Council of the European Patent Office has elected Benoît Battistelli as its new President.

The top 1000 UK companies invested more than £26 billion on developing new products, services and improving productivity in 2008.

A new study shows that the costs associated with a single new crop pest or disease agent have increased by 68.4 per cent in the past decade.

Redesigning PhD and masters programmes to attract the best researchers are at the centre of new proposals for maintaining the UK’s standing in scientific research.

The League of European Research Universities (LERU) has released a paper setting out its vision for doctoral education beyond 2010.